- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03202238
TenTaTorch: Venepuncture Made Easy
Venepuncture can be challenging, especially in patients with co-morbidities that predispose them to have inaccessible veins. Multiple unsuccessful venepuncture attempts compromise patient care. It causes pain, delays in obtaining blood samples for investigations and instituting intra-venous treatment.
Venepuncture assistive devices (VAD) include ultrasonography, and devices that utilize infra-red or transillumination. These are expensive, not widely available, and have not been rigorously proven to be effective. We have previously performed a preliminary study using an ordinary pen-torch for transillumination showed promising results. 95% of patients with known difficult venous access required two or less attempts for successful cannulation. It costs 35 times cheaper compared to the cheapest VAD in the market. The concept is promising but the technique cumbersome.
Building upon the concept of transillumination, the aim of this study is to develop an idiot-proof cost-effective pocket-sized VAD (TenTaTorch) to improve venepuncture success. A randomized controlled trial (RCT) will be conducted to determine its safety and efficacy. The TenTaTorch prototype will be modelled using Computer-Aided Design (Inventor®, Autodesk®, California, USA) and fabricated using 3D-printing, with silicon casting. Compared to existing VADs, TenTaTorch consists of finger-mounted LED light sources that allows greater manoeuvrability during transillumination.
We include adult patients aged 21 to 100 with difficult venous access (history of ≥3 consecutive attempts required for successful cannulation during the current admission) requiring non-emergent venepuncture in the RCT. Each patient undergoes venepuncture over the upper-limb using one of the following: Conventional Venepuncture without aid (Control 1); Veinlite® EMS (TransLite®, Texas, USA) (Control 2), a commercial transillumination device; our device TenTaTorch (Experimental Group).
Outcome measures include: successful cannulation within 2 attempts; duration of venepuncture; subjective user feedback. Fisher's exact and Kruskal-Wallis tests will be performed.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective randomized controlled trial. Patients with a history of difficult venepuncture who agreed to be enter into the study will be randomized into one of three groups using a sealed envelope system: Conventional Venepuncture without aid (Control 1); Veinlite® EMS (TransLite®, Texas, USA) (Control 2), a commercial transillumination device; our device TenTaTorch (Experimental Group). Hemodynamically unstable patients are excluded. The nurse involved in the care of the patient will attempt venepuncture over the upper limb. A group of nurses will be recruited before the start of patient recruitment. A maximum of 4 times attempts is allowed, before escalation to a doctor/phlebotomist.
A standardized venepuncture technique using standardized instruments will be utilized. A tourniquet is applied (Braun® International, USA). Veins will be localized using one of the above techniques. Both Veinlite and TenTaTorch utilize the concept of transillumination. Placing it onto the skin will cause the outlines of the veins to show up. Once a suitable vein is localized, the vein is marked with a pen. The area of the skin to be cannulated is disinfected with an alcohol wipe (Webcol®, Covidien®, USA). For the setting of IV cannulation, a standardized IV cannula (ranging 18 to 25 gauge) is used (Introcan Safety®, Braun®, USA). Normal saline (PosiFlush® 3ml, BD®, USA) will be used for flushing the cannula after successful cannulation. For blood taking, a syringe (Terumo®, Philippines) ranging from 2ml to 20ml and a needle (ranging between 18 to 25 gauge) (Venofix®, Braun®, USA) will be used. All instruments needed for venepuncture, including 4 IV cannula or 4 needles should be by the patient's bedside prior to the start of each venepuncture attempt. Duration of the procedure will be recorded using a stop watch. This is defined as the time (in minutes) from the start of attempt to localize a vein to its successful cannulation. Successful cannulation is defined either as the ability to flush 2ml of normal saline into the IV cannula or the ability to draw 2ml of blood from the vein. A post-procedure questionnaire will be filled up by the nurses after the attempt at venepuncture.
Outcome data include: number of attempts and duration needed for successful venepuncture. Patient data include: age, sex, race, body-mass index, history of intra-venous drug abuse, and renal function. Nurses who consent to join the study will be required to participate in a pre- trial tutorial which is estimated to last for 1 hour. During the tutorial, techniques of locating veins using TenTaTorch and by using the Veinlite® device will be taught. A standardized technique of venepuncture will also be taught. Tutorial will be in the form of slide- show presentation and hands-on training. During the hands-on training, nurses will attempt to identify veins on fellow trainees using both TenTaTorch and Veinlite®.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Elijah Cai, MBBS, MRCS
- Phone Number: 97203639
- Email: elijah_cai@nuhs.edu.sg
Study Contact Backup
- Name: Thiam Chye Lim, MD (Mal), FRCS, AM (Mal), FAMS
- Phone Number: 97599796
- Email: surlimtc@nus.edu.sg
Study Locations
-
-
-
Singapore, Singapore, 119074
- Recruiting
- National University Hospital
-
Contact:
- Elijah Cai, MBBS, MRCS
- Phone Number: 97203639
- Email: elijah_cai@nuhs.edu.sg
-
Contact:
- Thiam Chye Lim, MD, FRCS, AM, FAMS
- Phone Number: 97599796
- Email: surlimtc@nus.edu.sg
-
Principal Investigator:
- ELIJAH CAI, MBBS, MRCS
-
Principal Investigator:
- THIAM CHYE LIM, MD, FRCS, AM, FAMS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with difficult venous access: Patients who have a history of 3 or more venepuncture attempts required for successful cannulation
Exclusion Criteria:
- Patients who require emergency blood sampling
- Patients who require emergency insertion of intra-venous cannula
- Patients who are haemodynamically unstable
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Conventional
Venepuncture without the use of any venepuncture assistive device
|
Conventional venepuncture without use of any venepuncture assistive device.
|
|
Active Comparator: Veinlite
Commercial transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
|
Commercial transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
|
|
Experimental: TenTaTorch
Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
|
Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of attempts
Time Frame: Up to 1 day from the point of venepuncture attempt
|
Number of venepuncture attempts required for successful vein cannulation
|
Up to 1 day from the point of venepuncture attempt
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Duration of venepuncture
Time Frame: Up to 1 day from the point of venepuncture attempt
|
Duration required for successful vein cannulation
|
Up to 1 day from the point of venepuncture attempt
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subjective user feedback
Time Frame: Up to 1 day from the point of venepuncture attempt
|
User feedback on the ease of use of the device which would include information on the following:
|
Up to 1 day from the point of venepuncture attempt
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Elijah Cai, MBBS, MRCS, National University Hospital, Singapore
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018/01266
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vein Thrombosis
-
University of MaltaUniversità degli Studi dell'InsubriaCompletedCerebral Vein Thrombosis | Renal Vein Thrombosis | Retinal Vein Thrombosis | Splanchnic Vein Thrombosis | Ovarian Vein ThrombosisUnited States, Italy, France, Netherlands, Thailand, Spain, Israel, Slovenia, Canada, Malta
-
Università degli Studi dell'InsubriaOttawa Hospital Research InstituteUnknownPortal Vein Thrombosis | Mesenteric Vein Thrombosis | Splenic Vein ThrombosisCanada, Italy
-
University of AlbertaSanofi; Edmonton Civic Employees Research FundTerminatedPortal Vein Thrombosis | Splenic Vein ThrombosisCanada
-
University of OklahomaPfizerCompleted
-
University Medical Center GroningenCompletedSuspected Upper Extremity Deep Vein ThrombosisAustria, Netherlands, Italy, Belgium, Switzerland, Germany, United States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)CompletedDeep Vein Thrombosis | Venous Thromboembolism | Pulmonary Embolism | Malignant Neoplasm | Portal Vein Thrombosis | Metastatic Malignant Neoplasm | Cerebral Vein Thrombosis | Renal Vein Thrombosis | Gonadal Thrombosis | Hepatic Thrombosis | Mesenteric Thrombosis | Splenic ThrombosisUnited States
-
University of TorontoPfizer; Unity Health Toronto; Canadian Heart Research Centre; Ontario Association... and other collaboratorsUnknownThrombosis | Central Retinal Vein Occlusion | Retinal Vein Occlusion | Branch Retinal Vein Occlusion | Retinal Vein ThrombosisCanada
-
Assistance Publique - Hôpitaux de ParisCompletedDeep Vein Thrombosis | Chronic Portal Vein ThrombosisFrance
-
Assiut UniversityNot yet recruitingPortal Vein Thrombosis
-
Azienda Ospedaliera Universitaria PoliclinicoCompletedDeep Vein ThrombosisItaly
Clinical Trials on Conventional
-
Istanbul Medipol University HospitalActive, not recruiting
-
Riphah International UniversityCompletedChildren, AdultPakistan
-
Istanbul Demiroglu Bilim UniversityCompletedMuscle Weakness | Rehabilitation | Intensive Care Unit SyndromeTurkey
-
University of SalamancaCompleted
-
Biruni UniversityCompletedPain | Physical Therapy | Nonspecific Chronic Low Back Pain | Manuel TherapyTurkey (Türkiye)
-
University of AarhusGCP-unit at Aarhus University Hospital, Aarhus, Denmark; Danish Classical Homeopathy... and other collaboratorsCompleted
-
Qinhuangdao Hospital of Traditional Chinese MedicineShandong Public Health Clinical Center; Weifang Hospital of Traditional Chinese... and other collaboratorsRecruitingCognitive Impairment | Intracerebral HemorrhageChina
-
Aveiro UniversityFundação para a Ciência e a TecnologiaCompletedLower Respiratory Tract InfectionsPortugal
-
Mennallah Ahmed Mohamed Anwar ElgendyNot yet recruiting
-
Beijing Tiantan HospitalXiangya Hospital of Central South University; Zhongnan HospitalRecruitingPain | Herpes Zoster | Postherpetic NeuralgiaChina